A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis
| Autor: | Bianca Weinstock-Guttman, M. M. Uccelli, D. Gogol, J. E. Perryman, L. Neilley, R. P. Kinkel, M. Secic, S. VanderBrug Medendorp, Donald E. Goodkin |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis Randomization medicine.drug_class Anti-Inflammatory Agents Phases of clinical research Methylprednisolone Internal medicine medicine Humans Treatment Failure Adverse effect business.industry Multiple sclerosis Middle Aged medicine.disease Survival Analysis Surgery Regimen Tolerability Injections Intravenous Corticosteroid Female Neurology (clinical) business medicine.drug |
| Zdroj: | Neurology. 51:239-245 |
| ISSN: | 1526-632X 0028-3878 |
| Popis: | Objective: To compare the tolerability and efficacy of two doses of IV methylprednisolone in patients with secondary-progressive MS. Methods: IV methylprednisolone administered in high or low dose every other month for up to 2 years to 108 patients with secondary-progressive MS. Results: No significant difference in efficacy with the primary outcome, a comparison of the proportions of patients in each treatment group who experienced sustained progression of disability. A relative treatment effect was detected with the high-dose regimen as measured by the preplanned secondary analysis, a comparison of time to onset of sustained progression of disability. Drug-related adverse events were observed more frequently in high-dose recipients but serious drug-related adverse events were uncommon, and cessation of study drug was only required in one patient. Conclusion: The results of the secondary analysis of this study suggest that a phase III trial of corticosteroids for secondary-progressive MS is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|